Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SENIOR Trial
2022-500669-28-00Phase 2Withdrawn
- Sponsor
- University Hospital Odense
- Start
- Aug 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of dasatinib in osteoporosis and osteopenia, sponsored by University Hospital Odense. Primary endpoint: Change in circulating marker of bone resorption (CTX) at 20 weeks. Planned start Aug 2022; status: withdrawn.
02
Drugs
dasatinib
03
Conditions
osteoporosisosteopenia
Beyond the preview
Go deeper on 2022-500669-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500669-28-00.